<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ritodrine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00867</strong>&#160; (APRD00541)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Adrenergic beta-agonist used to control premature labor. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00867/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00867/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00867.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00867.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00867.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00867.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00867.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00867">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ritodrina</td><td>Spanish</td><td>INN</td></tr><tr><td>Ritodrinium</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ritodrine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000489/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000489/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IDLSITKDRVDKRV-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 323.128821282</li>
              <li>Average Mass: 323.814</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000489">DBSALT000489</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Yutopar</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li>
<li><a href="/mesh/adrenergic-beta-2-receptor-agonists">Adrenergic beta-2 Receptor Agonists</a></li>
<li><a href="/mesh/tocolytic-agents">Tocolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>26652-09-5</td></tr><tr><th>Weight</th><td>Average: 287.3535<br>Monoisotopic: 287.152143543</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>21</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IOVGROKTTNBUGK-SJCJKPOMSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[(1R,2S)-1-hydroxy-2-{[2-(4-hydroxyphenyl)ethyl]amino}propyl]phenol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C1=CC=C(O)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenols and Derivatives; Secondary Alcohols; 1,2-Aminoalcohols; Polyols; Enols; Dialkylamines; Polyamines</td></tr><tr><th>Substituents</th><td>phenol derivative; 1,2-aminoalcohol; secondary alcohol; polyol; polyamine; secondary amine; secondary aliphatic amine; enol; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment and prophylaxis of premature labour</td></tr><tr><th>Pharmacodynamics</th><td>Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle and, therefore, a decrease in premature uterine contractions. </td></tr><tr><th>Mechanism of action</th><td>Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>~56%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, by both the mother and fetus</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>1.7-2.6 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=64mg/kg (mice, IV); LD<sub>50</sub>=540 mg/kg (mice, oral); LD<sub>50</sub>=85 mg/kg (rat, IV)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9871</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8115</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5546</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.692</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.953</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8732</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6134</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6367</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5054</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5874</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9442</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6034</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8351</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7277</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7799
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9177
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8862
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2303 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7534
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5409
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abraxis pharmaceutical products</li>
<li>Hospira inc</li>
<li>Astrazeneca lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://global.abbottgrowth.com">Solvay Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>